ReviewJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing2025
Pulsed field ablation for paroxysmal supraventricular tachycardia: a systematic review and single-arm meta-analysis.
Review in Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulsed field ablation (PFA) is a novel, non-thermal technique for atrial fibrillation ablation that is currently under early investigation for paroxysmal supraventricular tachycardia (PSVT). We conducted a meta-analysis to evaluate the efficacy and safety of PFA in this setting.
methodsWe systematically searched PubMed, Embase, Cochrane Central, and Web of Science for studies on PFA in PSVT, including atrioventricular nodal reentrant tachycardia (AVNRT) and atrioventricular reentrant tachycardia (AVRT) with concealed or manifest accessory pathways. Outcomes included acute ablation success, success at 1, 3, and 6 months, and procedural/postoperative adverse events (AEs). Proportions were pooled using a random-effects model with arcsine transformation to account for extreme values. Analyses were conducted using R (v4.3.2).
resultsFive prospective single-arm studies involving 202 patients were included. The pooled acute success rate was 99.98% (95% CI: 99.29-100), with sustained success at 1, 3, and 6 months. Procedural and postoperative AE rates were low: 0.92% (95% CI: 0.00-4.88) and 0.06% (95% CI: 0.00-0.87), respectively. Subgroup analysis showed 100% acute success in AVNRT and in AVRT with concealed pathways, with high sustained success at 6 months. In AVRT with manifest pathways, acute success was 97.5% (95% CI: 84.74-100), maintained through follow-up.
conclusionIn this systematic review and meta-analysis, PFA demonstrated excellent safety and efficacy for the treatment of PSVT. Randomized controlled trials are warranted to establish the outcomes of PFA in this setting relative to thermal ablation.
Indexed as
Identifiers
41269503What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.